Literature DB >> 23936605

A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room.

Amy A Gelfand1, Peter J Goadsby.   

Abstract

Migraine is a common reason for visits to the emergency room. Attacks that lead patients to come to the emergency room are often more severe, refractory to home rescue medication, and have been going on for longer. All of these features make these attacks more challenging to treat. The purpose of this article is to review available evidence pertinent to the treatment of acute migraine in adults in the emergency department setting in order to provide neurologists with a rational approach to management. Drug classes and agents reviewed include opioids, dopamine receptor antagonists, triptans, nonsteroidal anti-inflammatory drugs, corticosteroids, and sodium valproate.

Entities:  

Keywords:  headache; migraine disorders; primary headache disorders; quality

Year:  2012        PMID: 23936605      PMCID: PMC3737484          DOI: 10.1177/1941874412439583

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  101 in total

Review 1.  Acute therapy for migraine headaches.

Authors:  Todd D Rozen
Journal:  Semin Neurol       Date:  2006-04       Impact factor: 3.420

2.  Avascular necrosis of bone after high doses of dexamethasone during neurosurgery.

Authors:  S Watkins; J R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-06

3.  The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.

Authors:  Randolph W Evans; Stewart J Tepper; Robert E Shapiro; Christina Sun-Edelstein; Gretchen E Tietjen
Journal:  Headache       Date:  2010-06       Impact factor: 5.887

Review 4.  Are butyrophenones effective for the treatment of primary headache in the emergency department?

Authors:  Lim Beng Leong; Anne-Maree Kelly
Journal:  CJEM       Date:  2011-03       Impact factor: 2.410

5.  A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine.

Authors:  Benjamin W Friedman; David Esses; Clemencia Solorzano; Niels Dua; Peter Greenwald; Radu Radulescu; Esther Chang; Michael Hochberg; Caron Campbell; Amish Aghera; Tyson Valentin; Joseph Paternoster; Polly Bijur; Richard B Lipton; E John Gallagher
Journal:  Ann Emerg Med       Date:  2007-11-19       Impact factor: 5.721

6.  Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache.

Authors:  Michael A Miller; Marc E Levsky; William Enslow; Alex Rosin
Journal:  Am J Emerg Med       Date:  2009-02       Impact factor: 2.469

7.  Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache.

Authors:  J Jones; S Pack; E Chun
Journal:  Am J Emerg Med       Date:  1996-05       Impact factor: 2.469

8.  Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine.

Authors:  Marcelo E Bigal; Alan M Rapoport; Richard B Lipton; Stewart J Tepper; Fred D Sheftell
Journal:  Headache       Date:  2003-04       Impact factor: 5.887

9.  Premonitory symptoms in migraine: an electronic diary study.

Authors:  N J Giffin; L Ruggiero; R B Lipton; S D Silberstein; J F Tvedskov; J Olesen; J Altman; P J Goadsby; A Macrae
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

10.  Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache.

Authors:  M Coppola; D M Yealy; R A Leibold
Journal:  Ann Emerg Med       Date:  1995-11       Impact factor: 5.721

View more
  11 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

Review 2.  Approach to Pediatric Intractable Migraine.

Authors:  Mohammed Alqahtani; Rebecca Barmherzig; Ana Marissa Lagman-Bartolome
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-04       Impact factor: 5.081

3.  In vivo imaging reveals that pregabalin inhibits cortical spreading depression and propagation to subcortical brain structures.

Authors:  Stuart M Cain; Barry Bohnet; Jeffrey LeDue; Andrew C Yung; Esperanza Garcia; John R Tyson; Sascha R A Alles; Huili Han; Arn M J M van den Maagdenberg; Piotr Kozlowski; Brian A MacVicar; Terrance P Snutch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 4.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

5.  Non-invasively triggered spreading depolarizations induce a rapid pro-inflammatory response in cerebral cortex.

Authors:  Tsubasa Takizawa; Tao Qin; Andreia Lopes de Morais; Kazutaka Sugimoto; Joon Yong Chung; Liza Morsett; Inge Mulder; Paul Fischer; Tomoaki Suzuki; Maryam Anzabi; Maximilian Böhm; Wen-Sheng Qu; Takeshi Yanagisawa; Suzanne Hickman; Joseph El Khoury; Michael J Whalen; Andrea M Harriott; David Y Chung; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-26       Impact factor: 6.200

Review 6.  Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins.

Authors:  Sara M Schaefer; Christopher H Gottschalk; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2015-07-14       Impact factor: 4.546

7.  Ketorolac versus Magnesium Sulfate in Migraine Headache Pain Management; a Preliminary Study.

Authors:  Hossein Delavar Kasmaei; Marzieh Amiri; Ahmed Negida; Samaneh Hajimollarabi; Nastaransadat Mahdavi
Journal:  Emerg (Tehran)       Date:  2017-01-08

8.  Can we define migraine patients with blood high-sensitivity C-reactive protein and galectin-3 levels in the emergency department?

Authors:  Mehtap Gürger; Metin Atescelik; Mustafa Yilmaz; Mustafa Yildiz; Hatice Kalayci; Mehmet Ali Kobat; Caner Fevzi Demir
Journal:  Arch Med Sci       Date:  2016-06-30       Impact factor: 3.318

Review 9.  The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

Authors:  Willem Sebastiaan van Hoogstraten; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2019-05-16       Impact factor: 7.277

10.  How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).

Authors:  Faustine L Dufka; Robert H Dworkin; Michael C Rowbotham
Journal:  Neurology       Date:  2014-09-05       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.